Kyverna Therapeutics (KYTX) investor relations material

Executive summary

• Lead program mivocabtagene autoleucel (miv-cel) advanced in late-stage clinical trials for neurologic autoimmune diseases, with positive Phase 2 results in SPS and gMG, and received FDA RMAT designation for naSPMS based on strong clinical data.

• Rolling BLA submission for SPS initiated, with completion targeted for Q4 2026 and commercial launch readiness activities underway.

• Enrollment ongoing in Phase 3 trial for gMG, with completion expected by mid-2027.

• Pipeline expansion includes additional autoimmune indications and new manufacturing agreements to support commercialization.

• Strengthened leadership team with new CFO, CCO, and Chief Legal and Compliance Officer appointments.

Financial highlights

• Net loss for Q2 2026 was $38.3 million, or $0.63 per share, a 9% improvement from Q2 2025.

• Operating expenses decreased 11% year-over-year for the quarter, primarily due to a 31% reduction in research and development costs.

• Cash, cash equivalents, and marketable securities totaled $199.4 million as of June 30, 2026.

• Research and development expenses were $24.8 million and general and administrative expenses were $14.8 million for Q2 2026.

• Operating runway expected into 2028, supported by cash position and loan facility.

Outlook and guidance

• Management expects existing cash and available financing to fund operations for at least the next 12 months, with operating runway into 2028.

• On track to complete rolling BLA submission for SPS in Q4 2026 and targeting commercial launch in 2027.

• Plans to report 12-month SPS data and longer-term gMG data in Q3 2026; expects to complete gMG Phase 3 enrollment by mid-2027.

• Update on PMS development strategy and additional Stanford Phase 1 IIT data expected by early 2027.

• Anticipates increased expenses as clinical programs progress, with continued investment in commercial infrastructure and manufacturing.